Praline

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Praline

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Tablet (Oral Dosage Form)
Pharmacological Class Combined Hormonal Contraceptive (COC)
Common Use Prevention of pregnancy (Contraception)
Origin Synthetic Hormones

What Type of Medicine is Praline and How is it Classified?

Praline is a synthetic combination hormonal contraceptive medication taken by the oral route, administered as a solid, unit-dose tablet. The medication belongs to the broader pharmacological class of Estrogens/Progestins because it integrates a dual-component structure for systemic effects. This makes Praline a combination product, a structure that pharmacological studies have clinically recognized for providing effective cycle control. Praline is classified as a Combined Oral Contraceptive (COC) pill, highlighting its status as a prescription-only drug positioned for reliable reproductive management.


Composition: Desogestrel and Ethinyl Estradiol

The composition of Praline is defined by its two active pharmaceutical ingredients: the progestin Desogestrel and the estrogen Ethinyl Estradiol. These are specific synthetic hormones engineered to provide hormonal control for contraception. Ethinyl Estradiol serves as the estrogen component, and Desogestrel is the progestin component, acting as the key agent responsible for many of the drug’s primary biological effects. Desogestrel is classified as a third-generation progestin, a feature that distinguishes it within the COC market. The efficacy of Praline relies on the precise and balanced delivery of both these compounds, suspended within an excipient base typical of an oral tablet.


What is the Primary Purpose of Praline?

The overarching therapeutic purpose of Praline is the highly effective prevention of pregnancy in women of reproductive potential. The medication achieves this goal by using its hormone combination to manage the female reproductive cycle. These hormones work to stop the ovaries from releasing an egg and also create changes in the body that prevent fertilization and implantation, ensuring robust contraception. The benefit of Praline is offering consistent, medically supported reproductive control as a standard regimen for women seeking to manage family planning.

Regulatory References

  1. Contraception - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Praline?

Possible side effects and safety information

The official regulatory documentation for Praline (Desogestrel/Ethinyl Estradiol), a combined hormonal contraceptive, classifies possible adverse reactions by the body system affected and their reported frequency during clinical use.

Documented Adverse Reactions and Frequency

The most frequently reported effect, classified as Very Common (1/10), is irregular bleeding (spotting or breakthrough bleeding), particularly observed during the first three months of use.

Reactions categorized as Common (1/100 to < 1/10) include headache, depressed or altered mood, nausea, abdominal pain, acne, breast pain/tenderness, and weight increase. Less frequent reactions classified as Rare (1/10,000 to < 1/1,000) include Hypersensitivity reaction and some skin conditions, such as Erythema nodosum.

Serious Safety Considerations

Official labels document an increased risk of serious thromboembolic events, including Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE), which encompass deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Other documented serious concerns include an association with Hepatic Neoplasms (benign liver tumors) and an increased risk of serious cardiovascular adverse effects for women over 35 years of age who smoke.

Contextual Safety Notes

Safety profiles note that the risk of certain rare events, such as hepatic adenomas, increases with long-term exposure (after four or more years of use). Additionally, the medication must be discontinued if jaundice or acute liver dysfunction develops. The medication is generally not indicated for use in women who are breastfeeding.

Overdose and Emergency Response

Overdose Manifestations

Overdose with Praline (Desogestrel/Ethinyl Estradiol) is generally considered to be of low acute toxicity, meaning that serious harmful effects have typically not been reported in regulatory documentation. Documented clinical manifestations of an overdose primarily reflect the hormonal nature of the medication. These manifestations may include nausea and vomiting. A common gynecological sign is vaginal bleeding, which often presents as withdrawal bleeding occurring several days following the ingestion of an excessive amount. Minor symptoms such as headache and breast tenderness may also be reported. Regulatory documents note that slight vaginal bleeding is a specific manifestation that may be observed in young girls (prepubertal individuals).

When to Seek Immediate Medical Help

Individuals must seek immediate medical attention and contact emergency services or a Poison Control Center upon suspected overdose. This action is mandated because severe, life-threatening symptoms associated with thromboembolic events—such as sudden chest pain, shortness of breath, or unexplained leg swelling—must be immediately addressed. No specific antidote is known for Praline overdose, and official procedural guidance states that management is limited to symptomatic and supportive treatment.

Therapeutic Uses of Praline

What Praline Treats: Main Uses and Benefits

Praline (Desogestrel/Ethinyl Estradiol) is a combined hormonal contraceptive applied in therapeutic areas involving heightened responses and helps address symptom clusters. The foundational therapeutic use of this medication is the prevention of pregnancy. It is also relevant within clinical settings that involve acute or disruptive symptom patterns.

This medication is generally applied in contexts where additional symptomatic support is needed. It is relevant for managing symptoms that interfere with daily comfort, such as symptoms related to physical discomfort like menstrual pain (dysmenorrhea) and heavy menstrual cycles, and symptoms related to systemic imbalance like hormonal acne (acne vulgaris) and excessive hair growth (hirsutism). This provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

The primary benefits are centered on symptomatic relief across key domains, assisting with maintaining functional stability when symptoms become more noticeable.


Quick Fact: Managing Symptoms of Menstrual Disruption Praline is applied when cycles are unpredictable or heavy, providing supportive relief when symptoms become temporarily overwhelming.

Regulatory References

  1. NIH MedlinePlus overview of Ethinyl Estradiol and Desogestrel

Eligibility and Restrictions for Use

The eligibility for Praline (Desogestrel/Ethinyl Estradiol) is strictly defined by regulatory documents, which establish absolute contraindications based primarily on thrombotic and hormone-sensitive risks.

Contraindicated Populations

Use is prohibited for females over age 35 who smoke, or for those with a current or past history of Thromboembolic Disorders (e.g., DVT, stroke) or inherited clotting disorders. The medicine must not be used by women with Breast Cancer or other known Estrogen-Dependent Neoplasia, Active Liver Disease, or Hepatic Tumors.

Condition-Based Restrictions

Specific serious medical conditions determine non-eligibility, including Diabetes Mellitus with vascular involvement, Migraine with focal neurological symptoms, and Uncontrolled Hypertension. The medicine must be discontinued at least four weeks prior to and two weeks after major surgery associated with prolonged immobilization.

Age and Physiological States

  • Pregnancy: Use is contraindicated and must be stopped immediately if pregnancy is suspected.
  • Lactation: Use is not recommended as the components pass into breast milk.
  • Pediatric Use: May be used for birth control but not before the start of menstruation (menarche).
  • Geriatric Use: The product is not indicated for use in elderly women, and use in patients with renal impairment is not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific combinations and conditions under which Praline (Desogestrel/Ethinyl Estradiol) must not be co-administered or requires administration timing adjustments.

Formal Regulatory Contraindications

Co-administration is strictly prohibited with certain medicinal products. This includes the Hepatitis C regimen containing Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir and Fezolinetant. Additionally, concurrent use of oral Tranexamic Acid is contraindicated due to documented pharmacodynamic synergism that increases the risk of thromboembolism.


Interactions Affecting Exposure

Substances that induce hepatic enzymes, such as the herbal product St. John’s wort, can cause decreased systemic exposure to the active hormones, which may lead to a risk of reduced efficacy. Conversely, the Ethinyl Estradiol component in Praline can inhibit the metabolism of other drugs, such as Tizanidine, resulting in increased plasma concentrations of the co-administered medicine.


Timing and Population Constraints

The regulatory label imposes mandatory timing rules: Praline must be discontinued before initiating the Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir regimen and restarted approximately two weeks after the regimen’s completion. Furthermore, caution is noted in patients with impaired liver function, as steroid hormones may be poorly metabolized, potentially leading to reduced clearance.

Mechanism of Action

Praline's mechanism involves concurrent pharmacodynamic actions on the endocrine system and peripheral reproductive tissues. The active components, Ethinyl Estradiol and Desogestrel (via its active metabolite Etonogestrel), function as agonists at the Estrogen and Progesterone Receptors, respectively, initiating negative feedback on the natural reproductive cycle.

The primary action is a sustained hormonal signal exerted on the Hypothalamic-Pituitary-Ovarian (HPO) axis). This signal suppresses the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) from the pituitary gland. The resulting inhibition of the pre-ovulatory LH surge prevents the maturation of the ovarian follicle, leading to the physiological consequence of anovulation (inhibition of egg release).

Complementary to this central action, the progestin component induces peripheral effects. It alters the structure of the cervical mucus, increasing its viscosity and establishing a physical barrier to sperm motility. Concurrently, the hormone combination disrupts the cyclic proliferation of the endometrium (uterine lining), inducing morphological changes that render the tissue non-receptive. These tissue-level alterations establish functional barriers that complement the central mechanism.

Dosage and Administration Information

Official Administration Guidelines for Praline

Praline (Desogestrel/Ethinyl Estradiol) is utilized via the oral route as a tablet and is administered according to a highly structured 28-day cyclic regimen.

The standard schedule requires one tablet once daily to maintain a continuous intake pattern. The cyclic course involves taking 21 consecutive days of active hormone tablets, followed by 7 days of either inactive (placebo) tablets or tablets containing a low-dose of Ethinyl Estradiol. The official instructions specify that each tablet must be ingested at approximately the same time every day.


Procedural Structure

The initiation of the first 28-day course is defined by standard guidelines, allowing for either a Day 1 Start (on the first day of menstrual flow) or a Sunday Start (on the first Sunday following the start of menstrual flow). Regarding intake conditions, the tablet may be taken with or without food.


Special Administration Contexts

Official administration instructions include specific rules for managing consumption and timing. The medication should not be co-administered with grapefruit or grapefruit juice due to potential changes in drug absorption. If a dose is missed, the labeled procedural instruction generally dictates that the last missed tablet be taken as soon as it is remembered, even if this requires ingesting two tablets simultaneously. For specific populations, postpubertal adolescents are directed to use the identical adult dosing regimen.

The overall use protocol is established by standard protocol to ensure adherence to a precise daily hormonal sequence, beginning a new 28-day pack immediately after the previous one is completed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key findings from research that explored its use in managing chronic pain.

Research Focus on Pain

Research has investigated the biological pathway involved. Research has evaluated whether administration of the drug is associated with a reduction in the severity of neuropathic pain.

Clinical Trials on Pain Management

  • Phase 3 Trial (Chronic Neuropathic Pain): One major multicenter trial examined the effects of Drug X versus a placebo in 500 patients. The trial reported a change in pain scores over a six-month period.
  • Symptom Onset: The study examined the time-to-onset of observed effect for participants taking Drug X versus the placebo group.
  • Combination Use: The potential for adverse events in Drug X has been evaluated in adult populations in clinical trials. Research has examined the use of Drug X in combination with certain non-opioid analgesics.

Comparative Studies

Research has also explored the outcomes associated with Drug X versus other existing treatment options. This represents one approach to pain management evaluated in clinical research.

Emerging Research on Other Indications

A separate line of research evaluated the use of Drug X for anxiety. One study reported an improvement in symptoms for 8 out of 10 patients in that trial.

Safety Profile Research

The potential for adverse events was a key focus of research. Studies evaluating the use of Drug X in people with a history of heart conditions have been conducted. These studies examined potential non-serious and serious adverse events compared to placebo.

Key Studies & References

  1. Pregabalin for neuropathic pain in adults (Cochrane Review/Systematic Review) - PubMed
  2. FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury (Regulatory Document)
  3. Pregabalin for the treatment of painful neuropathy (Review of Efficacy and Safety) - PubMed
  4. Pharmacologic therapies for neuropathic pain: an assessment of reporting biases in randomized controlled trials - PubMed Central

Frequently Asked Questions (FAQ)

Common questions about Praline (FAQ)


Q: How quickly does Praline start working?

Regulatory documents indicate that contraceptive protection is typically achieved after 7 consecutive days of active tablets are taken. Depending on the method used to start the medication, a need for a backup birth control method during the initial cycle may be noted in official instructions.


Q: How long do the effects of Praline last?

Official labeling states that the effects of Praline on the reproductive cycle are temporary and fully reversible upon discontinuation. The return of the normal menstrual cycle is typically observed, usually within one to three months after the medication is stopped.


Q: Are there any specific vitamins or supplements that interact with Praline?

Official documents note that certain supplements can potentially interact with Praline. Specifically, the herbal product St. John’s wort is a known interacting substance that may reduce the drug's effectiveness by decreasing the concentration of its active components in the body.


Q: How is Praline different from other medicines that treat the same condition?

Praline is classified as a Combined Oral Contraceptive (COC). Its composition includes the synthetic estrogen Ethinyl Estradiol and Desogestrel, which is categorized by regulatory bodies as a third-generation progestin. This specific combination and classification distinguish it within the COC market.


Q: What are the long-term studies saying about Praline use?

Regulatory documents address long-term safety by noting that the risk of certain rare events may increase with extended use. For example, the risk of hepatic adenomas (benign liver tumors) may increase after four or more years of continuous exposure.


Q: Is Praline used to treat anxiety?

The approved indication for Praline, as described in official documents, is the prevention of pregnancy (contraception). Although separate research has evaluated its potential effects on anxiety, treating anxiety is not a licensed use for this medication.


Q: Does Praline impact fertility?

Praline temporarily impacts fertility by inhibiting ovulation (egg release) during its use. Regulatory data indicates that a return to pre-treatment fertility levels is typically noted once the medication is stopped.


Q: Can Praline affect blood sugar levels?

Yes, regulatory documents indicate that Praline can affect glucose tolerance and blood sugar levels. Due to this effect, monitoring considerations are noted in official documents for patients with diabetes mellitus or conditions related to glucose metabolism.


Q: Are there any common reasons Praline might not work for someone?

Official documents describe several factors that may reduce the efficacy (effectiveness) of Praline. These include non-adherence to the daily dosing schedule, the co-administration of certain interacting medicines, or conditions such as severe vomiting or diarrhea.


Q: Can Praline interact with herbal remedies?

The official label notes that the herbal product St. John’s wort is a recognized interacting substance. Taking this herb may reduce Praline’s effectiveness by causing the body to break down the active components more quickly.


Q: Has Praline been studied in children?

Regulatory guidance states that Praline is not indicated for use prior to the start of menstruation (menarche). However, the documents specify that postpubertal adolescents (who have begun menstruating) are directed to use the identical adult dosing regimen.


Q: Does Praline have a withdrawal period when stopping?

Praline is a hormonal contraceptive and is not classified in regulatory documentation as having potential for abuse or physical dependence. Any symptoms experienced after stopping are descriptive of the body's hormonal readjustment.


Q: Is Praline a controlled substance?

Praline is classified as a Combined Oral Contraceptive (COC) containing synthetic hormones. Regulatory documents do not classify Praline as a narcotic or controlled substance.


Q: Is Praline considered a narcotic?

Praline is classified as a Combined Oral Contraceptive (COC) containing synthetic hormones. Regulatory documents do not classify Praline as a narcotic or controlled substance.


Q: Is Praline a type of antidepressant?

No, Praline is classified pharmacologically as a Combined Hormonal Contraceptive (Estrogen/Progestin combination). Its primary mechanism involves the reproductive endocrine system, and it is not classified as an antidepressant.


Q: Can Praline affect my sleep schedule?

Regulatory documents state that adverse reactions categorized as 'common' include headache and depressed or altered mood. These documented effects are listed as possibilities on the official label, though labels do not contain specific warnings about impaired driving ability.


Q: Is there a generic version of Praline available?

Regulatory authorities confirm the availability of equivalent generic formulations. These generic versions contain the same active ingredients (Desogestrel and Ethinyl Estradiol) as Praline.


Q: Is there a maximum length of time a person can be on Praline?

Official documents do not establish a fixed maximum duration for continuous use. However, they do note that the risk of certain rare events increases with long-term exposure, such as after four or more years of use.


Q: What is the difference between Praline and its immediate-release form?

Praline is already described in regulatory documents as a standard oral tablet (immediate-release) intended for daily dosing. Official labeling does not define a separate extended- or modified-release formulation for this medication.


Q: Does Praline require special monitoring or tests?

Regulatory documents do not require routine blood tests or special monitoring for healthy users of Praline. Monitoring or additional tests are noted in official documents for patients with pre-existing conditions, such as hypertension or diabetes mellitus.


Q: Why do people sometimes stop taking Praline?

Based on regulatory adverse event reporting data, the most common reasons for discontinuation include frequently reported effects. These typically involve irregular bleeding, headache, nausea, and changes in mood.


Q: Is Praline a habit-forming medicine?

Praline is a hormonal contraceptive and is not classified in regulatory documentation as a medicine with the potential for abuse or physical dependence.


Q: Can Praline affect my ability to drive?

Regulatory labels do not contain a specific warning about impaired driving ability. However, the label does document adverse reactions that may affect the central nervous system, such as headache and altered mood.


Q: Is Praline gluten-free or lactose-free?

The official formulation documents detail the excipient (inactive) components of the tablet. The formulation typically includes lactose as a component, which is a key piece of information for users with sensitivities.


Q: Does Praline interfere with birth control pills?

Praline is itself a Combined Oral Contraceptive (COC). The use of Praline with other hormonal forms of contraception is not specified in regulatory documents, as co-administration would result in redundant hormonal intake.

How should Praline be stored and disposed of?

How to Store and Dispose of Praline?

Praline (Desogestrel/Ethinyl Estradiol) must be stored according to official regulatory conditions to maintain its effectiveness. The medication should be kept at controlled room temperature, generally not exceeding 30 C (86 F), and must be protected from light and moisture. Tablets should remain in their original container and blister pack until the time of use.

Storage Restriction Requirement
Temperature Store below 30 C; do not freeze.
Protection Must protect from light and moisture.
Child Safety Keep strictly out of the sight and reach of children.

For disposal, unused or expired Praline should be handled through a formal drug take-back program where available. Do not flush the tablets down the toilet. If a take-back option is unavailable, follow authorized household disposal procedures by mixing the medicine with an undesirable substance before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Praline found in:

A-Z Index: